Thus, early detection of the EGFR mutation rate and its associated factors in lung tumors may present an important reference to individualize clinical treatment and improve treatment implementation in lung cancer, as well as to reduce the toxicity of drugs. The gene discussed is EGFR; the disease is lung carcinoma.